61
Participants
Start Date
April 30, 2016
Primary Completion Date
November 30, 2017
Study Completion Date
January 31, 2018
ubenimex
placebo
Weill Cornell Medicine, New York
Allegheny General Hospital, Pittsburgh
University of Pennsylvania Medical Center, Pittsburgh
University of Pennsylvania, Philadelphia
Johns Hopkins University, Pulmonary and Critical Care Medicine, Baltimore
The University of North Carolina at Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
University of Florida, Gainesville
Cleveland Clinic, Florida, Weston
University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
Kentuckiana Pulmonary Associates, Louisville
Cleveland Clinic Respiratory Institute, Cleveland
University of Michigan, Ann Arbor
Mayo Clinic College of Medicine, Rochester
Washington University, St Louis
UT Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
University Texas Health Science Center, San Antonio
University of Colorado Denver, Aurora
California Heart Center Foundation, An Affiliate of Cedars-Sinai Heart Institute, Cedars-Sinai Medical Care Foundation, Beverly Hills
UCSD Medical Center, La Jolla
Stanford University Medical Center, Stanford
Chest Medicine Associates, South Portland
Tufts Medical Center, Boston
Brigham and Women's Hospital, Boston
Boston University School of Medicine, Boston
Alpert Medical School of Brown University Rhode Island Hospital, Providence
London Health Sciences Centre, London
University of Ottawa Heart Institute, Ottawa
Toronto General Hospital, Toronto
Lead Sponsor
Eiger BioPharmaceuticals
INDUSTRY